ROBOSENSE
3.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense , the world’s leading autonomous driving LiDAR perception solution provider , announced today that the solid-state LiDAR RS-LiDAR-M1Simple(Simple Sensor Version ) is now ready for customer delivery, priced at $1,898 . The new RS-LiDAR-M1Simple is less than half the size of the previous version, with dimensions of 4.3” x 1.9” x 4.7” (110mm x 50mm x 120mm), and is equipped with enhanced hardware performance virtually equal to the serial production version provided to OEMs. The main body design of this automotive-grade solid-state LiDAR is finalized and ready for shipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200103005139/en/
In addition, RoboSense will demonstrate the world’s first smart solid-state LiDAR, the RS-LiDAR-M1Smart (Smart Sensor Version), at CES 2020 in Las Vegas, Booth 6138, LVCC North Hall from Jan 7-10, 2020 with an on-vehicle public road test. The RS-LiDAR-M1Smart main body is embedded with an AI perception algorithm that fully takes advantage of LiDAR’s potential to transform conventional 3D LiDAR sensors to a full data analysis and comprehension system.
“The RS-LiDAR-M1 is an optimal choice for the serial production of self-driving cars, far superior to mechanical LiDAR. The sooner solid-state LiDAR is used, the sooner production will be accelerated to mass-market levels,” said Mark Qiu, RoboSense COO.
RS-LiDAR-M1 Family Features:
- 125 laser beams with exceptional performance: the RS-LiDAR-M1 has a field of view of 120°*25°, which is the MEMS solid-state LiDAR’s largest field of view among released products worldwide. RoboSense uses 905nm lasers with low cost, automotive grade and small size instead of expensive 1550nm lasers. At the same time, RoboSense continuously breaks ranging ability limits to 150m at 10% NIST target, which is also MEMS solid-state LiDAR’s longest detection range.
- World’s smallest MEMS solid-state LiDAR: one-tenth the size of conventional 64-beam mechanical LiDAR. The RS-LiDAR-M1 can be easily embedded in the car’s body while still maintaining the vehicle’s appearance intact.
- Reduced parts from hundreds to dozens in comparison to traditional mechanical LiDARs for lower cost, shorter production time, and large-scale production capacity .
- Modular design: the scalability and layout flexibility of the optical module lay the foundation for subsequent MEMS LiDAR products and support the customization of products for different application cases.
- Stable and reliable: RoboSense fully implemented IATF16949 quality management system and ISO26262 functional safety standards, combining ISO16750 test requirement and other automotive-grade reliability specifications to verify the RS-LiDAR-M1 series of products.
- All-weather: In Vienna, Austria, the RS-LiDAR-M1 was tested for rain and fog under different light and wind speed conditions. The test results prove that the RS-LiDAR-M1 has met the standards, and the final mass-produced RS-LiDAR-M1 will adapt to all climatic and working conditions.
- Minimal wear and tear: as a solid-state LiDAR, the RS-LiDAR-M1 eliminates potential optoelectronic device failures due to mechanical rotation.
The RS-LiDAR-M1Smart is a comprehensive system with sensor hardware, AI point cloud algorithm, and chipsets, which provides an end-to-end customer environment perception solution. RoboSense’s powerful AI perception algorithm injects the sensor with structured semantic-level comprehensive information, focusing on the perception of moving objects.
For orders visit www.robosense.ai/buy or to contact a RoboSense account manager.
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, Samsung, ControlWorks, Aidrivers, and more. For more information, see the website at: http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005139/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom